Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Hematologic Neoplasms 2Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Biphenotypic, Acute 1

Interventions

Cytarabine 21Cyclophosphamide 21fludarabine 18Whole-Body Irradiation 18venetoclax 15fludarabine phosphate 15Specimen Handling 15Methotrexate 15Mycophenolic Acid 13Vincristine 9Biopsy 9merphos 8Granulocyte Colony-Stimulating Factor 8Filgrastim 8Dexamethasone 8calaspargase pegol 7blinatumomab 7Stem Cell Transplantation 7Peripheral Blood Stem Cell Transplantation 7Hydrocortisone 7Busulfan 7Azacitidine 7revumenib 6Tacrolimus 6Melphalan 6Idarubicin 6Daunorubicin 6Asparaginase 6X-Rays 5Thiotepa 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Biphenotypic, Acute × Homoharringtonine × 1 year × Clear all
NCT04874194 2025-11-03

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

M.D. Anderson Cancer Center

Phase 1/2 Terminated
24 enrolled 15 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡